Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2004

01-08-2004

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

Authors: Susan Burdette-Radoux, Richard G. Tozer, Reinhard C. Lohmann, Ian Quirt, D. Scott Ernst, Wendy Walsh, Nancy Wainman, A. Dimitrios Colevas, Elizabeth A. Eisenhauer

Published in: Investigational New Drugs | Issue 3/2004

Login to get access
Metadata
Title
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
Authors
Susan Burdette-Radoux
Richard G. Tozer
Reinhard C. Lohmann
Ian Quirt
D. Scott Ernst
Wendy Walsh
Nancy Wainman
A. Dimitrios Colevas
Elizabeth A. Eisenhauer
Publication date
01-08-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000026258.02846.1c

Other articles of this Issue 3/2004

Investigational New Drugs 3/2004 Go to the issue

OriginalPaper

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

OriginalPaper

A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells

OriginalPaper

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

OriginalPaper

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

OriginalPaper

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

OriginalPaper

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits